sirturo
j-c health care ltd - bedaquiline as fumarate - tablets - bedaquiline as fumarate 100 mg - bedaquiline - sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (mdr-tb) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
sirturo 100mg tablets
janssen-cilag ltd - bedaquiline fumarate - tablet - 100mg
sirturo
janssen-cilag international nv - bedaquiline fumarate - tuberculosis, multidrug-resistant - antimycobacterials - sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (mdr tb) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. consideration should be given to official guidance on the appropriate use of antibacterial agents.
sirturo 100mg tablets
pharmstandard-ufavita ojsc - bedaquiline (bedaquiline fumarate) - tablets - 100mg
sirturo tablets
pharmstandard-ufavita ojsc - bedaquiline (bedaquiline fumarate) - tablets - 100mg
sirturo
janssen-cilag (new zealand) ltd - bedaquiline fumarate 120.89mg equivalent to bedaquiline 100 mg; ; - tablet - 100 mg - active: bedaquiline fumarate 120.89mg equivalent to bedaquiline 100 mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 20 - sirturo is indicated in adult (greater than or equal to 18 years) and pediatric patients (12 years to less than 18 years of age and weighing at least 30 kg) as part of combination therapy of pulmonary tuberculosis (tb) due to multi-drug resistant mycobacterium tuberculosis.
sirturo 100mg tablets
johnson & johnson sdn. bhd. - bedaquiline fumarate -